iOrganBio

Executive Summary

iOrganBio is a Boston-based biotechnology company founded in 2021 that leverages advanced 3D bioprinting and stem cell technologies to develop bioengineered, patient-specific organ replacements. Addressing the critical shortage of donor organs, the company creates functional organ grafts at the intersection of regenerative medicine and synthetic biology. By combining patient-derived cells with biocompatible scaffolds, iOrganBio aims to produce organs that integrate seamlessly and reduce rejection risks. The company's platform holds transformative potential to revolutionize transplantation, offering hope to thousands on waiting lists. With a strong scientific foundation and a clear focus on clinical translation, iOrganBio is poised to become a key player in the organ replacement space. Its early-stage progress, however, means significant development and regulatory hurdles remain. The company's success will depend on demonstrating preclinical efficacy, securing strategic partnerships, and advancing manufacturing scalability.

Upcoming Catalysts (preview)

• Q4 2026Series A or B Financing Round70% success
• Q2 2027Preclinical Proof-of-Concept Data Release60% success
• Q1 2027Partnership with Major Transplant Center50% success